Calithera to shut down after failing to revive Takeda assets
Calithera Biosciences won’t make it to the second quarter.
After a November warning that it only had enough money to keep the lights on into the second quarter, the biotech’s board determined it was time to shut down.
The South San Francisco biotech, which bought two Phase II cancer assets from Takeda in the fall of 2021 to revive itself after a failure in renal cell carcinoma, will get rid of “substantially all our employees” and liquidate its assets, Calithera said Monday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.